SFA Honors David C. Fajgenbaum With Vision Of Hope Award At Stand Up To Sarcoma Gala
David Fajgenbaum, MD, MBA, MSc Sarcoma Foundation of America SFA's Vision of Hope Award will recognize physician-scientist David ...
precisionmedicineonline9 小时
FDA Panel Finds Limited Immunotherapy Benefit in PD-L1-Negative Gastric, Esophageal Cancer
The agency is considering whether to limit the indications of Keytruda, Opdivo, and Tevimbra to PD-L1-positive patients amid testing uncertainties.
MedPage Today11 小时
No Benefit for PD-1 Inhibitors in Certain Gastroesophageal Cancers, FDA Panel Says
By way of two resoundingly consistent votes, members of an FDA advisory committee agreed that PD-1 inhibitors do not have a favorable risk/benefit profile for gastroesophageal cancers with low PD-L1 ...
Targeted Oncology12 小时
Olomorasib Combo Elicits Favorable Efficacy in NSCLC
Olomorasib with pembrolizumab in the first-line showed a 77% overall response rate in patients with KRAS G12C–mutated ...
24/7 Wall St12 小时
Penny Stocks To Buy With Just $1500: PMVP, BOLD, SPRO
Do you have $1,500 you’d like to use to try investing in penny stocks? Some investments in the category can yield outsized ...
The American Journal of Managed Care12 小时
Combined Chemotherapy and Immunotherapy Improves Outcomes in PAH
An adult patient with pulmonary arterial hypertension (PAH) and metastatic lung adenocarcinoma showed significant clinical ...
The Pharma Letter19 小时
FDA panel votes against broader use of checkpoint blockers
A US Food and Drug Administration advisory committee meeting has recommended restricting the use of PD-1 inhibitors, in a ...
TME Pharma Provides Results of Third Exercise of Warrants Z
TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), ...